Items tagged with Drug-resistant TB

South Africa: World first programme to combat drug-resistant TB (post)

A groundbreaking new programme called BEAT Tuberculosis was launched in Port Elizabeth on March 27.

Levofloxacin pharmacokinetics in children with drug-resistant TB exposure (post)

According to data published in Antimicrobial Agents and Chemotherapy, the dosing recommendations regarding levofloxacin for the treatment and prevention of drug-resistant tuberculosis (DR-TB) in children may need to be re-evaluated.

WHO Western Pacific Region leads partner efforts to strengthen capacity towards scaling up programmatic response to drug-resistant TB (post)

12 April 2019 | Geneva: Following the release of the 2018 WHO consolidated guidelines on the treatment of drug-resistant tuberculosis, the Western Pacific Regional Office (WPRO) of WHO through its Green Light Committee (GLC) mechanism organized a consultant training workshop held from 27-29 March 2019 in Sydney, Australia. A total of 25 experts were equipped with the necessary knowledge and skills, including practical problem-solving, diplomacy and cultural competencies to ensure delivery of high quality support and constructive communication at all levels within the TB programme and government in line with WHO standards.

Now is the time for shorter all-oral regimens for multidrug-resistant TB (post)

The newly revised WHO guidelines for multidrug-resistant tuberculosis treatment includes major changes from the previous version, published in 2016. Notably, drugs such as bedaquiline, linezolid, and clofazimine are now strongly recommended for the treatment of multidrug-resistant tuberculosis. At the same time, older drugs, such as injectables, ethionamide, and para-aminosalicyclic acid, have been downgraded due to poor effectiveness and side-effect profiles. These new recommendations, if implemented, are expected to have a huge impact globally, increasing access of patients with multidrug-resistant tuberculosis to more effective and safer drug regimens that avoid debilitating side-effects, such as permanent hearing loss.

USAID's TB strategy as seen from Kyrgyzstan (post)

BISHKEK, Kyrgyzstan — When Eremina found out she had multidrug-resistant tuberculosis in 2017 and was headed to hospital, she was convinced she’d never go home. Two of her relatives with TB had disappeared into decrepit old sanatoriums about 17 years ago, and they had spent years getting treatment before eventually dying there. “So I said goodbye to everyone,” she said.

Сall for applications: Regional meeting on capacity building on DR-TB treatment in the EECA region (post)

The TB Europe Coalition (TBEC) announced a call for applications to participate in a regional meeting on capacity building of civil society to advocate for safe and affordable drug-resistant TB (DR-TB) treatment in the region of Eastern Europe and Central Asia (EECA). The meeting will take place on 18-20 June 2019 in Kiev, Ukraine.

Harvard undergrad's AI model helps to predict TB resistance (post)

One of the greatest challenges in treating tuberculosis—the top infectious killer worldwide, according to the World Health Organization (WHO)—is the bacterium's ability to shapeshift rapidly and become resistant to multiple drugs. Identifying resistant strains quickly and choosing the right antibiotics to treat them remains difficult for several reasons, including the bacterium's propensity to grow slowly in the lab, which can delay drug-sensitivity test results by as much as six weeks after initial diagnosis.

Low-level delamanid and bedaquiline resistance in extensively drug-resistant TB (post)

In a brief report published in Clinical Infectious Diseases, researchers reported a case of drug resistance against 2 recently approved antitubercular medications: delamanid and bedaquiline. Researchers presented a patient with extensively drug-resistant tuberculosis (TB), and highlighted the potential for the emergence and transmission of resistant Mycobacterium tuberculosis complex strains with more frequent use of these relatively new drugs.

Drug-resistant TB reversed in lab (post)

About 1.5 million people died of tuberculosis (TB) in 2017, making it the most lethal infectious disease worldwide. A growing rise in drug-resistant TB is a major obstacle to successfully treating the illness.

Phage therapy treats patient with drug-resistant bacterial infection (post)

Summary

Scientists have used an experimental therapy that relies on bacteria-infecting viruses collected, in part, through HHMI’s SEA-PHAGES program to fight a Mycobacterium infection in a 15-year-old girl.